A multi-centric, randomized, active controlled parallel group study to evaluate efficacy, tolerability and safety of Adalimumab (Zydus) and Adalimumab (Reference) in patients with Rheumatoid Arthritis.

Trial Profile

A multi-centric, randomized, active controlled parallel group study to evaluate efficacy, tolerability and safety of Adalimumab (Zydus) and Adalimumab (Reference) in patients with Rheumatoid Arthritis.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Sponsors Cadila Healthcare
  • Most Recent Events

    • 14 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top